# BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study

> **NCT02550743** · PHASE1 · TERMINATED · sponsor: **howard safran** · enrollment: 7 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** BYL719
- **DRUG:** Capecitabine
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT02550743
- **Lead sponsor:** howard safran
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-03
- **Primary completion:** 2018-11-16
- **Final completion:** 2018-11-16
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** lack of accural
- **Last updated:** 2021-03-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02550743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02550743, "BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02550743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*